Table 3.
Study | Age (Mean ± SD) |
Disease Duration (Mean ± SD) |
Medication | HY Stage (Mean ± SD) |
Design | Site | Coil | Intensity | Frequency | No. of Stimuli | Duration | Evaluation Time | Total Sample |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shimamato 2001 [35] | 65.1 ± 28 | 7 ± 4.2 | ON | 3.1 ± 0.9 | Controlled blinded | Frontal | C | 0.4T | 0.2 | 60 | 8 wk (1/wk) | Immediate | 18 |
Dragasevic 2002 [31] | 59.9 ± 8.5 | ON | 2 ± 0.7 | Uncontrolled | Bilateral frontal | C | 110% AMT | 0.5 | 200 | 10 | 2 h and 20 d | 10 | |
Ikeguchi 2003 [36] | 68.8 ± 6.8 | 7.8 ± 4.5 | ON | 2.9 ± 1.1 | Controlled | Bilateral frontal | C | 70% output | 0.2 | 60 | 2 wk (3/wk) | Immediate | 16 |
Okabe 2003 [23] | 67.2 ± 8.2 | 8.8 ± 5.1 | OFF | 3.1 ± 0.9 | RCT blinded | Vertex | C | 110% RMT | 0.2 | 100 | 8 wk (1/wk) | 4 and 8 wk | 85 |
Buhmann 2004 [32] | 58.4 ± 10.5 | ON | 2.1 ± 0.6 | Uncontrolled | PMD | F8 | 80% AMT | 1 | 1200 | 1 | Immediate | 19 | |
Lefauheur 2004 [25] | 64 ± 6.9 | 11 ± 3.4 | OFF | 3.4 ± 0.7 | RCT blinded | Left M1 | F8 | 80% RMT | 0.5 | 600 | 1 | Immediate (20 min) | 12 |
Baumer 2009 [33] | 62.2 ± 6.5 | 10.7 ± 2.9 | OFF | 3.1 ± 0.6 | Uncontrolled | PMD | F8 | 80% AMT | 1 | 1200 | 1 | Immediate | 15 |
Arias 2010 [29] | ON | RCT | Vertex | C | 90% RMT | 1 | 100 | 1 | Immediate and 1 wk | 18 | |||
Filipovic 2010 [27] | 64.5 ± 9.4 | 15.6 ± 5.6 | OFF | 3.3 ± 2.2 | Controlled blinded | M1 | F8 | 90% RMT | 1 | 1800 | 1 | 1 d | 10 |
Shirota 2013 [11] | 68.8 ± 7.6 | 8.5 ± 7.3 | ON | 2.9 ± 1.1 | RCT, double blind | SMA | F8 | 110% AMT | 1 | 1000 | 8 wk (1/wk) | 1 and 12 wk | 106 |
HY = Hoehn and Yahr scale; AMT = active motor threshold; RCT = randomized controlled trial; RMT = rest motor threshold; PMD = premotor dorsal cortex; M1 = primary motor cortex; SMA = supplementary motor area; MT = rest motor threshold; 5PMD = premotor dorsal cortex; 6M1 = primary motor cortex; 7SMA = supplementary motor area.